SAN JUAN, Puerto Rico--(BUSINESS WIRE)--Wovenware, a nearshore provider of Artificial Intelligence (AI) and digital transformation solutions, announced today that it has been chosen as the software and AI development partner of choice for CDI Labs, a Puerto Rico-based global biotechnology firm. Through the partnership, Wovenware is creating the technology for a next-generation COVID-19 rapid antigen single-use, self-testing kit.
“Wovenware is our technology partner of choice as we innovate a new approach to advanced COVID-19 self-testing,” said Ignacio Pino, President and CEO, CDI Labs. “The company’s deep bench of expertise in mobile app development and AI for life sciences will allow us to meet surging market demand for easy-to-use, immediate and accurate self-testing.”
Providing results via any mobile device, the first generation of the test kits will allow consumers to administer tests from the comfort of their homes in a matter of minutes. They will be able to download the mobile app to any iOS or Android device and the app will guide them through the test-taking process. As part of the development process for next-generation kits, the Wovenware team has trained a computer vision model to detect individual test kit components in order to provide an official positive or negative diagnosis in real-time. It will detect 99% of positive test cases.
“CDI Labs is at the forefront of protein research and we have deep expertise in computer vision, software development and human-centric design,” said Christian Gonzalez, CEO, Wovenware. “Through this unique combination of talent, we’re able to deliver an easy-to-use mobile app that can improve consumer health and remove the stress from COVID-19 testing. Once again, we’re able to see first-hand the power of technology working with scientists to solve global challenges.”
About CDI Labs
CDI Labs was founded on the belief that many future discoveries depend on a deeper understanding of individual proteins and their interactions with the immune system. CDI Labs combines proprietary bioinformatics, vast proteomic libraries and a deep expertise in synthetic biology to create mMabs™: the first proteome-validated monospecific monoclonal antibodies, and Antygen™, the multi-dimensional immune-profiling platform. The Company is spearheading the antigen-specific revolution that will help unravel some of the greatest mysteries in human health. The COVID-19 rapid antigen test will be manufactured and distributed world-wide by CDI Labs’ affiliate SentryAg, Inc.
About Wovenware
As a design-driven software firm, Wovenware delivers custom and patented AI, computer vision and other digital transformation solutions and services that create measurable value for customers. Through its nearshore capabilities, the company has become the partner of choice for organizations needing to re-engineer their systems and processes to increase profitability, boost user experience and seize new market opportunities. Wovenware leverages a multidisciplinary team of world-class experience designers, software engineers, data scientists and data specialists to create solutions for cloud transformation, advanced AI innovation and application modernization. Headquartered in Puerto Rico, Wovenware partners with customers across North America and around the world.
Visit us on the web at www.wovenware.com, or connect with us on Twitter, Facebook, LinkedIn or Instagram.